Sort
48,018 grants matching “immunotherapy”
Repolarizing the Tumor and Metastatic Microenvironments to Treat Patients with Pancreatic Cancer
$490,237Scott Andrew Gerber · University Of Rochester · R01 · FY2024 · CA
Intelligent treatment planning for cancer radiotherapy
$490,133Steve Bin Jiang · Ut Southwestern Medical Center · R01 · FY2020 · CA
Intelligent treatment planning for cancer radiotherapy
$490,133Steve Bin Jiang · Ut Southwestern Medical Center · R01 · FY2021 · CA
Regulation of JAK/STAT pathways in the eye
$490,093Charles E Egwuagu · National Eye Institute · ZIA · FY2022 · EY
FOXA1 regulates cytokine signaling and immune landscape in prostate cancer through ARID1A
$490,082Jindan Yu · Emory University · R01 · FY2024 · CA
Modeling Antibody-induced Immune Responses by NK cells in Mice and Humans (Resubmission 1)
$490,076Jayajit Das · Research Inst Nationwide Children'S Hosp · R01 · FY2025 · AI
Targeting replication stress signaling to overcome immune evasion in small cell lung cancer
$490,061Triparna Sen · Icahn School Of Medicine At Mount Sinai · R01 · FY2022 · CA
Targeting replication stress signaling to overcome immune evasion in small cell lung cancer
$490,061Triparna Sen · Icahn School Of Medicine At Mount Sinai · R01 · FY2025 · CA
Regulatory B cells in the amelioration of immune-mediated periodontal disease
$490,000Xiaozhe Han · Ada Forsyth Institute, Inc. · R01 · FY2017 · DE
Co-targeting the HER3 oncogenic signaling circuitry and PD-1 as a novel multimodal precision immunotherapy for HNSCC
$489,974J. Silvio Gutkind · University Of California, San Diego · R01 · FY2022 · CA
Co-targeting the HER3 oncogenic signaling circuitry and PD-1 as a novel multimodal precision immunotherapy for HNSCC
$489,974J. Silvio Gutkind · University Of California, San Diego · R01 · FY2023 · CA
Delineating developmental programs driving tumorigenesis in triple-negative breast cancer
$489,960Aaron M Newman · Stanford University · R01 · FY2024 · CA
The joint WCM-NYGC Center for Functional and Clinical Interpretation of Tumor Profiles
$489,879Olivier Elemento · Weill Medical Coll Of Cornell Univ · U24 · FY2016 · CA
Tumor-specific CD8+ Tc9 cells activate host CD4+ T cells to control antigen-lost tumors
$489,857Qing Yi · Methodist Hospital Research Institute · R01 · FY2025 · CA
Tumor-specific CD8+ Tc9 cells activate host CD4+ T cells to control antigen-lost tumors
$489,857Qing Yi · Methodist Hospital Research Institute · R01 · FY2024 · CA
Regulation of memory T cell differentiation and long-term maintenance
$489,800Ananda W Goldrath · University Of Florida · P01 · FY2022 · AI
Genomics and Computational Biology Shared Resource
$489,709Kelly A Frazer · University Of California, San Diego · P30 · FY2020 · CA
Project 2:Nanoparticle-based Immune Modulators in Cancer Therapy & Vaccines
$489,587Jenny P.y. Ting · Univ Of North Carolina Chapel Hill · U54 · FY2017 · CA
Mechanisms of treatment failure in chimeric antigen receptor T cell therapy
$489,534Brian Till · Fred Hutchinson Cancer Center · R01 · FY2022 · CA
Mechanisms of treatment failure in chimeric antigen receptor T cell therapy
$489,533Brian Till · Fred Hutchinson Cancer Center · R01 · FY2023 · CA
Overcoming obstacles in structural elucidation of B cell antigen receptor assembly and lateral interaction
$489,500Hao Wu · Boston Children'S Hospital · R21 · FY2025 · AI
Nortriptyline-mediated attenuation of alpha-synuclein pathology in Parkinson's disease
$489,414Timothy J. Collier · Michigan State University · R01 · FY2015 · NS
EGFR Peptides as Vaccines in Anti-Tumor Immunity
$489,408Mark J. Mamula · L2 Diagnostics, Llc · R42 · FY2011 · CA
Eastern Cooperative Oncology Group
$489,398Fox Chase Cancer Center · U10 · FY2004 · CA
EASTERN COOPERATIVE ONCOLOGY GROUP
$489,398Fox Chase Cancer Center · U10 · FY2003 · CA